Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction.
The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 13, 24 | -0.25 Increased by +41.86% | -0.23 Decreased by -8.70% |
| May 9, 24 | -0.26 Increased by +48.00% | -0.24 Decreased by -8.33% |
| Mar 13, 24 | -0.26 Increased by +68.67% | -0.31 Increased by +16.13% |
| Nov 9, 23 | -0.34 Increased by +74.81% | -0.38 Increased by +10.53% |
| Aug 14, 23 | -0.43 Increased by +60.19% | -0.42 Decreased by -2.38% |
| May 9, 23 | -0.50 Increased by +37.50% | -0.69 Increased by +27.54% |
| Mar 16, 23 | -0.83 Decreased by -9.21% | -0.83 |
| Nov 14, 22 | -1.35 Decreased by -90.14% | -1.13 Decreased by -19.47% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | N/A Decreased by N/A% | -12.51 M Decreased by -76.03% | - - |
| Jun 30, 24 | 0.00 Decreased by N/A% | -8.46 M Decreased by -2.69% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -6.49 M Increased by +32.11% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -5.48 M Increased by +50.17% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -7.11 M Increased by +47.57% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -8.24 M Increased by +24.22% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -9.56 M Decreased by -20.77% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -10.99 M Decreased by -53.68% | Decreased by N/A% Decreased by N/A% |